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Abstract
PURPOSE—We investigated the prognostic utility of onset age at first signs and symptoms (SS) 
to predict onset age at loss of ambulation (LOA) for childhood-onset Duchenne and Becker 
Muscular Dystrophies (DBMD).
METHODS—Our cohort comprised male cases with DBMD ascertained by the population-based 
Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). Adjusted 
hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional 
hazards models for associations between onset ages of first SS and LOA. Covariates controlled for 
were corticosteroid use, family history of DBMD, birth year, race/ethnicity, and MD STARnet site. 
Onset age at first SS was considered as a continuous and as a categorical variable.
RESULTS—A one-year increase in onset age at first SS was significantly associated with a 10% 
reduction in annual risk of LOA (HR = 0.90, CI = 0.87–0.94). Treating onset age at first SS as a 
categorical variable yielded a similar association (≥ 5 years: referent; ≥ 3 to < 5 years: HR = 1.36, 
CI = 1.02–1.81; 18 months to < 3 years: HR = 1.72, CI = 1.31–2.26; < 18 months: HR = 1.52, CI 
= 1.14–2.02).
CONCLUSIONS—Earlier onset age at first SS is associated with earlier onset age at LOA and 
may have clinical utility in differentiating childhood-onset Duchenne and Becker muscular 
dystrophies.
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1. Introduction
Childhood-onset dystrophinopathies, such as Duchenne and Becker Muscular Dystrophies 
(DBMD), are allelic, X-linked recessive neuromuscular disorders caused by mutations in the 
dystrophin gene. Mutations that disrupt the mRNA reading frame lead to complete lack of 
dystrophin and cause the severe Duchenne (DMD) phenotype, whereas in-frame mutations 
that allow for translation of some shorter but partially functional dystrophin cause the milder 
Becker (BMD) phenotype. This “reading frame” rule is accurate in predicting phenotype 
severity in about 92% of cases [1]. Exceptions to this rule exist and are likely due to 
alternative initiation sites [2], exon-skipping, and differences in intronic deletion breakpoints 
as well as genetic and environmental modifiers [3–5].
Historically, loss of ambulation (LOA) has been used as the key clinical milestone to 
describe disease progression with early LOA associated with a more severe disease 
manifestation [6]. Clinically, DMD patients are defined by onset of symptoms by age 5 years 
and, historically, LOA before age 12, whereas BMD patients have onset of symptoms after 
age 5 years (mean age 11 years) and remain ambulatory beyond age 15 [6]. Patients who 
lose ambulation between ages 12 and 15 years have been clinically classified as intermediate 
cases (IMD). Treatment with prednisone and deflazacort has been found to prolong 
ambulation by one to three years for DMD patients thereby slowing disease progression and 
complicating clinical diagnosis [7–9]. As a result, age at LOA alone may no longer be a 
useful diagnostic indicator of disease severity. An alternative approach would be to identify 
risk factors for LOA identified in the early stages of disease onset and use these factors 
along with LOA to describe progression of muscle weakness. One such indicator would be 
the age at which the first signs of muscle weakness are observed. Although onset of such 
symptoms has been used clinically, the prognostic utility of onset age at first signs or 
symptoms (SS) has not been studied in a large cohort of patients. As such, we investigated 
the association between age at first SS and age at LOA using a large population-based cohort 
of males with childhood-onset dystrophinopathy identi-fied by the Muscular Dystrophy 
Surveillance Tracking and Research Network (MD STARnet).
2. Methods
2.1. Study population and case classification
The MD STARnet cohort is the first and only population-based cohort of childhood-onset 
dystrophinopathy cases in the United States (U.S.) and is funded by the Centers for Disease 
Control and Prevention (CDC) [10]. Starting in 2004, the MD STARnet retrospectively 
identified and longitudinally followed cases with DBMD who were diagnosed before age 21 
years, born since 1982, and resided in an MD STARnet site (Arizona, Colorado, Iowa, 
Western New York State); Georgia and Hawaii joined the MD STARnet in 2005 and 2008, 
respectively. Multiple sources were used to identify potential cases including neuromuscular 
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clinics, hospitals and hospital discharge databases, private physicians, service units for 
children with special healthcare needs, and birth defects surveillance programs. Since the 
start of surveillance in 2004, all health and vital status information was systematically 
collected annually by trained abstractors from medical records for cases in the cohort until 
December 31, 2011, or sooner if the case was deceased or moved out of a surveillance 
catchment area. A full description of the MD STARnet surveillance methodology has been 
published [10,11]. Colorado, Georgia, Iowa, and New York State expanded public health 
authority to permit active case finding and record abstraction; institutional review board 
approval was obtained for these surveillance activities in Arizona (University of Arizona) 
and Hawaii (Hawaii Department of Health).
Key clinical and diagnostic data were used to assign a case status (definite, probable, 
possible, female, asymptomatic, or not DBMD) and were then reviewed by a committee of 
neuromuscular clinicians representing each site to assign the final case status [12]. Cases 
that were definite or probable had either DNA or muscle biopsy confirmation.
2.2. Outcome definition
The primary outcome variable was onset age at LOA, calculated either from the earliest age 
at which full-time wheelchair use was recorded or from the earliest age when ambulation 
was recorded as ceased. Cases with conflicting information on earliest age when full-time 
wheelchair use began or when ambulation ceased were excluded (n = 47, 5.3%). Other 
exclusions were female cases diagnosed with DMD (n = 9, 1.0%) and those with unknown 
age at first SS (n = 4, 0.5%) (Fig. 1).
2.3. Independent variable definition
The primary independent variable was the onset age at first SS, which was calculated from 
the earliest onset of the following signs and symptoms: trouble rising/Gowers’ sign, trouble 
walking/running/jumping, frequent falling/clumsiness, inability to keep up with peers, 
abnormal gait, loss of motor skills, gross motor delay, or muscle weakness. The onset age at 
first SS was analyzed as a continuous variable and as a categorical variable (< 18 months, 
≥18 months to < 3 years, ≥ 3 years to < 5 years, and ≥ 5 years).
2.4. Covariates
The covariates examined and measured in cases, were corticosteroid use, family history of 
DBMD, birth year, race/ethnicity, and MD STARnet site, as well as maternal education at 
the time of birth of the case child. Corticosteroid use was categorized according to the age at 
start of corticosteroids and percentage of time on corticosteroids until ambulation ceased or 
last known age when ambulatory (never used corticosteroids, started after age 7 years and on 
≥ 80% of the time, started after age 7 years and on < 80% of the time, started between ages 
5–7 years and on ≥ 80% of the time, started between ages 5–7 years and on < 80% of the 
time, started before age 5 years and on ≥ 80% of the time, and started before age 5 years and 
on < 80% of the time). Family history was defined as ‘known’ if another family member was 
known to be diagnosed with DBMD before the birth of the case; otherwise, it was coded as 
known after the case child’s birth or as no known family history. Other covariates included: 
birth year (continuous), MD STARnet site (AZ, CO, GA, HI, IA, NY), race/ethnicity (White 
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non-Hispanic, Black non-Hispanic, Hispanic/Latino, and Other), and maternal education at 
the time of the child’s birth (< high school, high school and/or GED, some college or two 
year degree, Bachelor’s degree or higher).
2.5. Statistical analyses
For cases who were still walking at the last follow-up contact (n = 330, 40.0%), their age 
was censored at date of this contact. Cox proportional hazards models were used to evaluate 
the association between the onset age at first SS and onset age at LOA, adjusting for 
covariates. Onset age at first SS was modeled as both a continuous variable and a categorical 
variable. To identify relevant covariates, multiple model selection procedures were used to 
select the most parsimonious model and included forward selection, backward elimination, 
and stepwise selection. Corticosteroid use was forced to be included in all models. A liberal 
significance level of 25% was used for variables to either enter or exit the model. After 
selection of the most parsimonious model for covariates, onset age at first SS was added to 
the model and a Wald test was performed to examine the statistical significance of this 
variable. Results for associations with onset age at LOA were reported as adjusted hazard 
ratios (HRs) with their corresponding 95% confidence intervals (CIs). Data analyses were 
performed using SAS software (SAS Institute Inc., Cary, NC, USA) [13].
3. Results
The final dataset, which included birth years 1982–2009, comprised 825 cases of which over 
one-half were non-Hispanic white (59%). The onset age at first SS was > 5 years for 29% of 
cases and 69% of cases had no known family history of DBMD prior to case birth. 
Approximately one-half of cases had ever taken corticosteroids (Table 1). Of the 495 cases 
(60%) who had lost ambulation, 69% did so before age 12 years, 27% between ages 12 and 
16, and 3% after age 16 (data not shown). Among these non-ambulatory cases, the average 
onset age at LOA was 11.1 years (standard deviation [SD] = 2.5 years, range = 5.5–24.3 
years). The average age at the last follow-up visit for the 330 cases who were still walking 
was 10.6 years (SD = 5.3 years, range = 1.8–27.9 years).
Unadjusted Kaplan-Meier curves showing the distribution of onset age at LOA by onset age 
at first SS are presented in Fig. 2. The median onset ages at LOA for the earliest two onset 
age at first SS groups (< 18 months and ≥ 18 months to < 3 years) were similar (median 
[interquartile range] ages = 11.02 years [10.41, 11.98] and 10.99 years [10.23, 11.30], 
respectively). For those cases whose onset age at first SS was between 3 and 5 years, a later 
median onset age at LOA was estimated (11.59 years [10.88, 12.18]). The median onset age 
at LOA was latest for those with onset age at first SS ≥ 5 years (12.83 years [12.17, 13.45]).
The three model selection strategies (backward, forward, and stepwise) all yielded the 
identical covariate model for onset age at LOA, with corticosteroid use, family history of 
DBMD, birth year, race/ethnicity, and MD STARnet site included in the model. This 
analysis included 716 (87%) of the original 825 cases, due to missing values for case family 
history of DBMD (n = 42) and race/ethnicity (n = 75).
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Table 2 displays the HR estimates for the association between onset age at first SS and onset 
age at LOA. When onset age at first SS was treated as a continuous variable, a one-year 
increase in this onset age was associated with a 10% reduction in annual risk of LOA (HR = 
0.90, 95% CI = 0.87–0.94). When onset age at first SS was entered as a categorical variable, 
a generally progressive increased annual risk of LOA with earlier onset age at first SS was 
observed, except in the group with youngest onset age at first SS (≥ 5 years: HR = 1.00 
[referent group]; ≥ 3 to < 5 years: HR = 1.36, 95% CI = 1.02–1.81; ≥ 18 months to < 3 
years: HR = 1.72, 95% CI = 1.31–2.26; < 18 months: HR = 1.52, 95% CI = 1.14–2.02]) 
(Table 2).
4. Discussion
Our findings from this population-based cohort show that earlier onset age at first SS is a 
risk factor for a more rapid progression of muscle weakness, as measured by onset age at 
LOA, after controlling for corticosteroid use, family history of DBMD, birth year, race/
ethnicity, and MD STARnet site. The model with onset age at first SS as a continuous 
variable showed that a one-year increase in this onset age was associated with a 10% 
reduction in annual risk of LOA. However, results from the model with onset age at first SS 
entered as a categorical variable suggested that the relationship between the log-hazard and 
onset age at first SS may not be linear. The HR representing the relative risk for LOA 
progressively increased in magnitude from the oldest onset age at first SS group (> 5 years, 
HR = 1.00) to the next-to-youngest onset age at first SS group (≥18 months to < 3 years, HR 
= 1.72), but the HR for the youngest onset age group at first SS was slightly lower in 
magnitude (< 18 months, HR = 1.52). Retrospective recall of onset age at first SS by the 
family may be difficult, particularly with a delay in diagnosis, and the associated 
measurement error may be one possible explanation for the observed non-linear association.
Comparison of our findings to available studies is difficult due to the absence of studies, and 
differences in study design and analysis among those reporting natural history data. A few 
other studies have examined early risk factors for clinical progression. For example, 
Humbertclaude et al. created disease severity groups based on onset age at LOA and 
reported on the earliest symptom of motor function loss across these groups [14]. The 
earliest symptom among the most severe classification (loss of running ability) occurred, on 
average, around age 5 years and 5 months among steroid-naïve DMD patients. Desguerre et 
al. used age and type of symptom onset, muscle strength at 8 years and intelligence quotient 
to identify four different subsets of DMD patients [15]. The group with earliest onset age at 
LOA (mean age = 9 years) had an average onset age at initial symptoms of 1.3 years. This 
study, however, did not conduct an analysis of onset age at LOA as an outcome variable and, 
thus, did not report differences in the distribution of onset age at LOA as a function of onset 
age at first SS. Finally, Ziter et al. found that the rapidity of loss of strength varied by 
individuals and could be clearly established by age seven, thus predicting future 
deterioration [16].
There is great interest in using genotyping, imaging techniques and other methods to 
identify markers that predict disease severity and possibly variability in disease progression 
[17]. For example, genetic studies have examined specific genotypes for LTBP4 and SSP1 
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and have shown these genotypes to modify disease progression in some series (3;4). Poorer 
motor outcomes, including onset age at LOA, have been shown to be associated with 
increased endomysial fibrosis identified through morphometry [18]. Cacchiarelli et al. found 
that high serum levels of muscle-specific microRNAs corresponded to low ambulant activity, 
and that microRNA quantification was a better diagnostic marker than CK activity [19]. 
Magnetic resonance imaging and spectroscopy are also showing great promise as techniques 
to measure muscle pathology (e.g., lipid infiltration, muscle damage and inflammation/
edema) that might be used to predict progression [20]. The findings of more severe disease 
progression among those with early onset age at first SS may help refine disease phenotypes 
for studies using these techniques, thereby improving the prediction of progression.
4.1. Study strengths and limitations
To our knowledge, the MD STARnet cohort is the largest population-based cohort of DBMD 
in the U.S. Most other U.S. studies have used samples derived from single specialty clinics 
[7] or self-reports from patients enrolling in registries [21,22] and carry possible selection 
bias limiting generalization of the observed associations reported. The comprehensive, 
population-based surveillance approach used by the MD STARnet entails more systematic 
collection of clinical data and increases the generalizability of our findings to the larger 
DBMD population. Limitations of the MD STARnet are common to all observational studies 
based on medical record abstraction. Specifically, clinical records may not include all 
important information on factors that influence the natural history of DBMD. For example, 
details of home physical therapy programs and diet are difficult to extract. Also, the onset 
age at first SS is generally collected retrospectively and may be subject to recall bias, or 
inconsistent documentation in the medical record. Additionally, we used complete LOA as 
an objective endpoint that is consistently recorded in all medical records, but there could 
also be a subjective element in its determination if, for example, report of full-time 
wheelchair use relied occasionally on parent recall instead of clinical evaluation. Decisions a 
family makes regarding using walking aids longer instead of using a wheelchair earlier 
would also impact determination of age at LOA.
5. Conclusion
Individuals with childhood-onset dystrophinopathies display a continuum of clinical 
severity. Even among those with typical DMD, there is significant variability in the rate of 
progression [14,15]. Clinical decisions and counseling are required early in the course of 
disease; therefore, it is important to identify factors that can aid in predicting course, 
particularly ones that are non-invasive, inexpensive, and readily measured. We observed that 
earlier onset age at first SS was associated with earlier onset age at LOA in the MD 
STARnet cohort suggesting that early motor dysfunction is one factor with prognostic utility 
that could be considered when planning clinical management decisions. It might also be a 
factor to consider when stratifying boys in clinical trials given its prognostic significance.
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Fig. 1. 
Selection of cases for final analytic data set.
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Fig. 2. 
Kaplan-Meier curves showing loss of ambulation (LOA) over time by age at onset of first 
signs/symptoms (SS).
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Table 1
Characteristics of boys with DBMD in the MD STARnet cohort, 1982–2009
Characteristics N (%)
Age at first signs/symptoms
 < 18 months 182 (22.1%)
 18 months to < 3 years 220 (26.7%)
 ≥ 3 years to < 5 years 185 (22.4%)
 ≥ 5 years 238 (28.9%)
Corticosteroid use
 None 417 (50.6%)
 Age > 7, < 80% of the time 52 (6.3%)
 Age 5–7, < 80% of the time 28 (3.4%)
 Age < 5, < 80% of the time 8 (1.0%)
 Age > 7, ≥ 80% of the time 146 (17.7%)
 Age 5–7, ≥ 80% of the time 119 (14.4%)
 Age < 5, ≥ 80% of the time 55 (6.7%)
Family history of DBMD
 Known before/during pregnancy 207 (25.1%)
 Known after child’s birth due to diagnosed relative 32 (3.9%)
 No known family history 544 (65.9%)
Missing 42 (5.1%)
Birth year
 1982–1984 61 (7.4%)
 1985–1989 175 (21.2%)
 1990–1994 203 (24.6%)
 1995–1999 198 (24.0%)
 2000–2004 152 (18.4%)
 2005–2009 36 (4.4%)
Race/ethnicity
 White, non-Hispanic 485 (58.8%)
 Black, non-Hispanic 61 (7.4%)
 Hispanic/Latino 165 (20.0%)
 Other 39 (4.7%)
 Unknown 75 (9.1%)
MD STARnet site
 Arizona 177 (21.5%)
 Colorado 187 (22.7%)
 Georgia 225 (27.3%)
 Hawaii 16 (1.9%)
 Iowa 111 (13.5%)
 New York 109 (13.2%)
Mother’s education level
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Characteristics N (%)
 < High school 134 (16.2%)
 High school 184 (22.3%)
 Some college 110 (13.3%)
 Bachelor’s degree or higher 95 (11.5%)
 Missing 302 (36.6%)
DBMD = Duchenne or Becker Muscular Dystrophy; MD STARnet = Muscular Dystrophy Surveillance, Tracking, and Research Network.
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Table 2
Associations between age at onset of first signs or symptoms (SS) and age at loss of ambulation (LOA) among 
males with DBMD in the MD STARnet cohort, 1982–2009
Variable Hazard Ratio* 95% CI P-value
Model 1: Continuous
 Age at first SS 0.90 (0.87, 0.94) < 0.0001
Model 2: Categorical
 Age first SS
  < 18 months 1.52 (1.14, 2.02) 0.001
  18 months ≥ SS < 3 years 1.72 (1.31, 2.26)
  3 years ≥ SS < 5 years 1.36 (1.02, 1.81)
  ≥ 5 years 1.00
*Adjusted for race/ethnicity, family history of DBMD, year of birth, corticosteroid use, and MD STARnet site; CI = confidence interval; DBMD = 
Duchenne and Becker muscular dystrophies; MDSTARnet = Muscular Dystrophy Surveillance, Tracking, and Research Network.
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